| Nov 14 |
Fortress Biotech: Q3 Earnings Snapshot
|
| Nov 14 |
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
|
| Nov 14 |
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
|
| Nov 12 |
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
|
| Nov 12 |
Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
|
| Nov 12 |
Mustang Bio Receives Positive Listing Determination from Nasdaq
|
| Nov 4 |
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
|
| Oct 31 |
Fortress Biotech Insiders Placed Bullish Bets Worth US$4.49m
|
| Oct 25 |
Highbridge Capital Management's Strategic Acquisition of Fortress Biotech Shares
|
| Oct 25 |
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference
|
